Valeant's Rise and Steep Fall: What Comes Next?
Michael Waterhouse, equity analyst at Morningstar, discusses the future for Valeant Pharmaceuticals after the drugmaker lowered its sales and profit forecast for 2016, sending shares tumbling more than 30 percent. He speaks on "Bloomberg Markets." (Source: Bloomberg)
Most Recent Videos
Infosys CEO Resigns After Criticism From Founders
54:20 - Infosys Ltd. Chief Executive Officer Vishal Sikka has stepped down following criticism from the company’s founder. Chief Operating Officer Pravin Rao will become interim CEO. Bloomberg's Caroline Hyde reports on "Bloomberg Technology." (Source: Bloomberg)